Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American BrainTumor Consortium Study

PURPOSE: To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its me...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Cancer Res
Hoofdauteurs: Loghin, Monica E., Prados, Michael D., Wen, Patrick, Junck, Larry, Lieberman, Frank, Fine, Howard, Fink, Karen L., Metha, Minesh, Kuhn, John, Lamborn, Kathleen, Chang, Susan M., Cloughesy, Timothy, DeAngelis, Lisa M., Robins, Ian H., Aldape, Kenneth D., AlfredYung, W.K.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2007
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802002/
https://ncbi.nlm.nih.gov/pubmed/18056194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-07-0874
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items